NDA 215341 · Bayer Hlthcare
Kerendia
Finerenone · Oral · Nonsteroidal Mineralocorticoid-Receptor Antagonist
NovelPriority reviewCDER novel approval, Jul 9, 2021: To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jul 9, 2021
Approved uses
4
Original approval plus efficacy supplements
Registered trials
83
22 Phase 3, 28 recruiting
FAERS reports
3,299
2,292 serious, 253 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
Kerendia is indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM) [see Clinical Studies (14.1) ] . reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM) [see Clinical Studies (14.2) ] . reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% [see Clinical Studies (14.3) ] . Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to: reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with Type 2 diabetes mellitus (T2DM). ( 1 ) reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease in adults with CKD associated with Type 1 diabetes mellitus (T1DM). ( 1 ) reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. ( 1 )
Mechanism: Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR mediated sodium reabsorption and MR overactivation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. MR overactivation is thought to contribute to fibrosis and inflammation. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors.
Therapeutic areas: Cardiovascular and metabolic · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 2026 Supplement 11 · Efficacy · priority review LetterLabel
- Jul 11, 2025 Supplement 9 · Efficacy · priority review LabelLetter
- Sep 1, 2022 Supplement 1 · Efficacy LetterLabel
- Jul 9, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- KERENDIA · FINERENONE 20MG · TABLET, ORAL · Prescription
- KERENDIA · FINERENONE 40MG · TABLET, ORAL · Prescription
- KERENDIA · FINERENONE 10MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Finerenone" as an intervention, any sponsor and status, largest first.
- Effect of MRA on Cardiovascular Disease in Patients With Hypertension and HyperaldosteronemiaPivotal-lookingEnrolling by invitation
Nanfang LiAcademic, hospital or other
NCT05688579 · 8,000 participants (planned) · Start Apr 16, 2023 · Primary completion Dec 31, 2026
Drug: Mineralocorticoid Receptor Antagonists(MRAs) · For: Hypertension; Hyperaldosteronaemia
Sites: Ürümqi, China
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02545049 · 7,352 participants · Start Sep 17, 2015 · Primary completion Feb 2, 2021
Drug: Finerenone (BAY94-8862); Placebo · For: Diabetic Kidney Disease
Sites: Birmingham, Alabama; Fort Payne, Alabama; Huntsville, Alabama · 975 sites in all
BayerBayer (BAYRY)
NCT04435626 · 6,016 participants · Start Sep 14, 2020 · Primary completion May 15, 2024
Drug: Finerenone (BAY94-8862) · For: Heart Failure
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 661 sites in all
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02540993 · 5,734 participants · Start Sep 17, 2015 · Primary completion Apr 14, 2020
Drug: Finerenone (BAY94-8862); Placebo · For: Chronic Kidney Disease
Sites: Birmingham, Alabama; Fort Payne, Alabama; Huntsville, Alabama · 978 sites in all
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPivotal-lookingRecruiting
Colorado Prevention CenterAcademic, hospital or other
NCT06008197 · 5,200 participants (planned) · Start Jan 17, 2024 · Primary completion Nov 2027
Drug: Finerenone; Placebo · For: Heart Failure; Acute Heart Failure
Sites: Birmingham, Alabama; Fairhope, Alabama; Huntsville, Alabama · 356 sites in all
- Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailurePivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07575672 · 2,832 participants (planned) · Start Oct 9, 2026 · Primary completion Dec 31, 2029
Drug: Finerenone; Placebo · For: HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation); Finerenone
Sites: Bengbu, China; Hefei, China; Beijing, China · 61 sites in all
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsPivotal-lookingRecruiting
Colorado Prevention CenterAcademic, hospital or other
NCT06033950 · 2,600 participants (planned) · Start Aug 20, 2024 · Primary completion Aug 2026
Drug: Finerenone; Placebo · For: Heart Failure
Sites: Fairhope, Alabama; Phoenix, Arizona; Yuma, Arizona · 176 sites in all
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectPivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06058585 · 2,000 participants (planned) · Start Sep 4, 2024 · Primary completion Dec 31, 2029
Drug: Finerenone; Placebo Finerenone and 2 more · For: Chronic Kidney Diseases
Sites: Garran, Australia; Kingswood, Australia; Kogarah, Australia · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- glomerular filtration rate decreased335
- hyperkalaemia283
- blood creatinine increased246
- death202
- blood potassium increased197
- renal impairment158
- dizziness124
- acute kidney injury116
- suspected off label use107
- diarrhoea106
- nausea106
- off label use96
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 56 |
| 2022 | 393 |
| 2023 | 531 |
| 2024 | 634 |
| 2025 | 811 |
| 2026 | 872 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kerendia (Finerenone)
2024 spending
$396M
Beneficiaries
88,208
403,577 claims
Per beneficiary
$4,493
$21.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,849,278 |
| 2022 | $74,078,624 |
| 2023 | $269,681,549 |
| 2024 | $396,302,773 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R, Filippatos G, Pitt B, et al. · Eur Heart J 2022 · Clinical Trial, Phase III, Multicenter Study
- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Vaduganathan M, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Multicenter Study
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
Nong K, Jeppesen BT, Shi Q, et al. · BMJ 2025 · Systematic Review, Network Meta-Analysis
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.